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Abstract
The Coronavirus Disease-2019 (COVID-19) pandemic has exacted a heavy toll on patients with 
alcohol-associated liver disease (ALD) and alcohol use disorder (AUD). The collective burden of 
ALD and AUD was large and growing prior to the COVID-19 pandemic. There is accumulating 
evidence that this pandemic has had a large direct effect on these patients and is likely to produce 
indirect effects via delays in care, psychological strain, and increased alcohol use. Now a year into the 
pandemic, it is important that clinicians fully understand the effects of the COVID-19 pandemic on 
patients with ALD and AUD. To fill existing gaps in knowledge, the scientific community must set 
research priorities for patients with ALD regarding their risk of COVID-19, prevention/treatment of 
COVID-19, changes in alcohol use during the pandemic, best use of AUD treatments in the COVID-
19 era, and downstream effects of this pandemic on ALD. Conclusion: The COVID-19 pandemic has 
already inflicted disproportionate harms on patients with ALD and ongoing, focused research efforts 
will be critical to better understand the direct and collateral effects of this pandemic on ALD.
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Introduction
Coronavirus Disease-2019 (COVID-19), caused by severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) viral infection, has had important direct and indirect effects on patients 
with alcohol-associated liver disease (ALD). Prior to the COVID-19 pandemic, the global toll of ALD 
was sizable and COVID-19 has inflicted disproportionate negative effects on this population. Early 
data suggest that patients with chronic liver disease, and particularly those with ALD, may be at 
greater risk of mortality if infected by SARS-CoV-2 (1-3). Furthermore, the COVID-19 pandemic and 
resulting social and economic stressors have contributed to increased psychological strain for many 
individuals, including those with alcohol use disorder (AUD) and ALD. As a result, the pandemic is 
likely to enact collateral damage on this population via delays in care and increases in alcohol use. 
Changes in alcohol use patterns may lead to alcohol-associated hepatitis and liver-related mortality. 
At the current time, approximately a year since SARS-CoV-2 virus was first identified (4), it is 
important that we assess the effects of this pandemic on ALD patients and define research priorities 
needed to mitigate these effects.
Pre-COVID-19 ALD Burden
In the pre-COVID-19 era, the burden of AUD and ALD was large and growing. National data 
from the US show that the prevalence of AUD and high-risk drinking has increased in recent years 
(5). The diagnosis of alcohol-associated cirrhosis is on the rise (6) and there have been corresponding 
increases in liver transplantation from ALD and alcohol-associated hepatitis (7, 8). There have also 
been larger numbers of ALD-related hospitalizations (9) and inpatient costs attributable to ALD now 
total more than every other liver disease etiology combined (10, 11). 
Based on national death certificate data, mortality from ALD is also on the rise (12). Of 
concern, the average annual percentage changes in mortality rates have been most pronounced among 
younger individuals and women. Average annual percentage change (AAPC) in mortality in women 
age 25-34 years was 6.07 (95% CI 2.95-9.28) compared to women age 65-74 with AAPC 1.81 (95% 
CI 0.92-2.71).
Alcohol cessation can arrest or even reverse ALD (13) and AUD treatment is associated with 
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(14-16). Before COVID-19, implementation of AUD counseling or pharmacotherapy was only used 
among 10-14% of patients with alcohol-associated cirrhosis (5, 14, 15). Furthermore, there are 
concerning sex-based disparities with lower utilization of AUD treatment in women. This may be due 
to attitudinal barriers, more perceived stigma, and conflicting family or child care responsibilities 
(14).
Outcomes of ALD Patients with COVID-19
There are many reasons why alcohol use and ALD may predispose to worse outcomes from 
COVID-19. First, alcohol use and associated liver disease disrupts the innate and adaptive immune 
systems by affecting the survival and function of immune cells important in mounting a defense 
against viral infections (17, 18). Second, chronic alcohol consumption is associated with an increased 
susceptibility to acute respiratory distress syndrome (19-21). This may be related to alcohol’s direct 
effects on immune function in addition to alveolar epithelial dysfunction and decreased concentration 
of pulmonary antioxidants in individuals with chronic alcohol abuse (22). Third, patients with alcohol 
use disorder often have other comorbidities including metabolic syndrome, chronic kidney disease 
and tobacco use, which have been independently associated with severe COVID-19 outcomes  (23-
25). 
While patients with cirrhosis do not appear to be at increased risk for SARS-CoV-2 
acquisition (26), there is now some direct evidence that among patients with liver disease, those with 
ALD fare worse with COVID-19. Data from an international registry study that included 179 patients 
(24%) with ALD demonstrated that cirrhosis, and particularly decompensated cirrhosis, was 
associated with worse outcomes from COVID-19 (1). Furthermore, even adjusting for potential 
confounders including medical comorbidities, ALD etiology was associated with an increased risk of 
mortality in COVID-19. Similar findings were reported in a US multi-center study in which 
decompensated cirrhosis, hepatocellular carcinoma, and ALD were independent risk factors for 
mortality in patients with COVID-19 (2).
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Effects of the COVID-19 pandemic unrelated to SARS-CoV-2 infection itself may prove to 
have the biggest effect on ALD patients. Undoubtedly COVID-19 will enact massive collateral 
damage via the effects of deferred care, medication non-adherence, increased consumption of food 
and more high-risk alcohol use (27, 28). The pathophysiology of ALD is complex but overall alcohol 
dose and pattern of consumption are both strongly implicated in the risk of ALD (29). Increased 
alcohol consumption during the COVID-19 pandemic therefore has the potential to lead to increased 
morbidity and mortality. 
A number of COVID-19-related factors have the potential to increase alcohol use in patients 
with AUD or excess drinking. Factors that increase alcohol use may include adverse economic effects 
resulting from the COVID-19 pandemic, disruptions in work and education, psychosocial stressors 
associated with limitations on social gatherings, social isolation with decreased or lack of social 
support system, and shifts in alcohol consumption from bars/restaurants to at-home use (30).
Epidemiologic and marketing data during early days in the pandemic showed a spike in 
alcohol use in the general population. In April 2020, online sales of alcohol in the US were up 477% 
and brick-and-mortar sales were up 26% compared to sales from the year prior (31). Post-pandemic 
increases in alcohol purchases were most pronounced in younger adults, households with children 
younger than 18 years, and ethnic minorities (32). Similar findings were demonstrated in Canada, 
where there was a 38% relative increase in monthly alcohol sales in March 2020 compared to March 
2019 (33). Online sales may have lower cost per unit of alcohol, which could lead to increased 
consumption. Additionally, sales of larger packs of alcohol including boxes of wine, large volume 
(e.g. 1.75 liter) liquor bottles, and 30-packs of beer have all increased compared to previous years 
(31). Emerging data suggest that individuals, and particularly females, are engaging in an increased 
frequency of alcohol consumption and binge drinking (34, 35). In sum these data imply that 
increasing trends in alcohol sales are translating to increased alcohol consumption and are not 
attributable to increased alcohol stockpiling alone.
Some concerning trends have also been shown in individuals with AUD. Researchers in the 
United Kingdom identified individuals with pre-existing alcohol disorders and performed a cross-
sectional telephone survey two months after their national lockdown (36). Of 182 participants, 24% 
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bottles of wine, 1.5 bottles of spirits, or 16 pints of beer) per week after lockdown. In contrast, only 
19% reported a decrease in alcohol intake.
There are already some early signs that accelerations in alcohol-associated health effects 
among women may worsen in the COVID-19 era. During the pandemic, women have taken on a 
disproportionate amount of work at home and have borne a higher economic burden than men (37). 
There are some early data suggesting that this may be leading to larger increases in alcohol use and 
alcohol-associated health effects in women (38). As mentioned previously, there is lower utilization 
of AUD treatment among women (14). It is unclear how this may change in the COVID-19 era given 
expanded options for AUD treatment, including virtual counseling and online Alcoholics Anonymous 
meetings.
Downstream Effects of COVID-19 on ALD Patients
Given the association between alcohol use and poor outcomes in ALD, COVID-19-related 
changes in alcohol consumption have the potential to lead to direct alcohol-associated health effects, 
including alcohol-associated hepatitis and liver-related mortality. Furthermore, depending on program 
requirements for pre-transplant abstinence, alcohol relapses could lead to decreased transplant 
referrals and waitlist drop-off in pre-liver transplant patients. While it is still too early to fully assess 
the effect of changes in alcohol consumption patterns in the wake of the COVID-19 pandemic, there 
are some early data that are concerning.
In the spring of 2020, as the US COVID-19 outbreak was beginning, there were some signs 
that cirrhosis patients were delaying care. Data from the National Veterans Affairs healthcare system 
show a rapid drop off in cirrhosis admissions beginning in March of 2020 compared to historic data 
from the prior year (39). Patients admitted later had higher model for end-stage liver disease (MELD) 
scores, suggesting that only the sickest patients were coming in for care. In addition, there was a very 
slight increase in the proportion of cirrhosis-related hospitalizations among patients with ALD 
compared to other etiologies.
Increases in alcohol consumption in the COVID-19 era also have the potential to contribute 
directly to the burden of alcohol-associated liver disease. Some have raised concern that increased 
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associated hepatitis (30). Early anecdotal reports that alcohol-associated hospitalizations have 
increased (40) are now corroborated by a single-center study demonstrating an increasing number of 
hospitalizations and liver transplants among patients with ALD in the COVID-19 era (41).
Changes in alcohol consumption in the COVID-19 era could also have huge implications on 
patients listed for transplantation. In the previously mentioned telephone survey conducted in the 
United Kingdom (36), 17% of patients who were abstinent prior to the lockdown experienced a 
relapse during lockdown. If similar patterns of alcohol relapse are occurring in patients listed for 
transplant this could negatively impact the listing status of many patients.
Call for Ongoing Investigation of COVID-19 and ALD
To mitigate the downstream effects of the COVID-19 pandemic on patients with ALD, there is 
an urgent unmet need to identify, investigate, and address clinically-important questions relevant to 
this population (Table 1). These research priorities should fit within the larger framework of ongoing 
strategies to address the growing burden of ALD and AUD (42). Specific areas that deserve further 
attention include COVID-19 outcomes in ALD, with and without cirrhosis; COVID-19 treatments for 
patients with chronic liver disease and ALD; safety and efficacy of the COVID-19 vaccine in patients 
with ALD; the effects of the COVID-19 pandemic on alcohol use patterns; the efficacy of remote 
AUD counseling such as digital or virtual technology and use of telemedicine; and changes in the 
incidence of alcohol-associated health effects including alcohol-associated hepatitis, alcohol-
associated-acute-on-chronic liver failure, alcohol-associated cirrhosis, and decompensations in 
patients with established cirrhosis. Furthermore, additional discussion of transplant listing policies for 
patients who relapse during the pandemic is critical given the unique and challenging stressors related 
to the COVID-19 pandemic.
Such research efforts have the potential to inform the clinical care of patients with ALD 
including tailored COVID-19 treatment guidelines and guidance on the optimal use of corticosteroids 
in patients with severe alcohol-associated hepatitis infected with SARS-CoV-2. This work could also 
have immediate policy implications including informing vaccination strategies and recommendations 
regarding shielding (i.e. minimizing all face-to-face contact for extremely clinically vulnerable) for 
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Additionally, these efforts could explore potential disparities in alcohol consumption and ALD by sex 
and race/ethnicity, determine care delivery models best suited to address AUD, and inform transplant 
listing decisions for patients who experience relapse during the COVID-19 pandemic.
The National Institutes of Health (NIH)/National Institute on Alcohol Abuse and Alcoholism 
(NIAAA) have prioritized investigation of alcohol use in the era of COVID-19. There are new 
Requests for Applications (RFA) for grants that address the relationship between alcohol consumption 
and outcomes of COVID-19, including the impact of alcohol misuse on COVID-19 incidence and 
severity and effects of pandemic-related restrictions on high-risk drinking and AUD (43).
Conclusions
In conclusion, prior to COVID-19, alcohol-associated liver disease had a massive and growing 
burden. Early in the COVID-19 pandemic, we observed worse outcomes from COVID-19 infections 
among patients with ALD. There has also been significant collateral damage related to the pandemic, 
including psychosocial strain and limited access to healthcare, which may lead to more high-risk 
drinking. Increases in the frequency and amount of alcohol intake have the potential to increase 
morbidity and mortality in patients with ALD. There are already some early signs that ALD patients 
are experiencing poor outcomes in the wake of COVID-19, including delays in care and an increase in 
alcohol-associated hepatitis. Furthermore, an increase in relapses or an inability to confirm sobriety in 
the COVID-19 era has the potential to lead to transplant listing challenges for many patients. Ongoing 
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Table 1. Research Priorities for COVID-19 and Alcohol-Associated Liver Disease (ALD)
Research Priority Clinical/Policy Implications
Risk and Outcomes of COVID-19 in ALD
Incidence of COVID-19 
infection in ALD
- Inform recommendations regarding shielding (i.e. avoidance of all person-
to-person contact in extremely vulnerable) for patients with ALD
COVID-19 outcomes in patients 
with ALD
- Better understanding of relative influences of alcohol use and underlying 
liver disease on COVID-19 outcomes
- Tailored clinical care guidelines for ALD patients
Treatment of alcohol-associated 
hepatitis and COVID-19
- Determine the optimal use of corticosteroids in patients with alcohol-
associated hepatitis and COVID-19
COVID-19 Therapies/Vaccination
Efficacy of COVID-19 therapies 
in ALD
- Provide clinical guidance for SARS-CoV-2 infections in patients with ALD
Risks of COVID-19 therapies in 
ALD
- Provide clinical guidance for SARS-CoV-2 infections in patients with ALD
- Better inform patients on expected risks of these therapies
Safety and efficacy of COVID-
19 vaccinations in ALD
- Magnitude/duration of vaccine response
- Effect of liver disease severity on vaccine response
- Need for additional booster doses for adequate immunologic response and 
protection
- Risk of liver injury
Alcohol Use during COVID-19 Pandemic
Patterns of alcohol consumption 
during the COVID-19 pandemic
- Determine if increased online sales of alcohol translate into increases in 
overall consumption
- Inform policy that could reduce harms from alcohol use during the 
pandemic
Factors associated with 
unhealthy alcohol use during 
COVID-19
Ascertain policy priorities (e.g. alcohol pricing, depression/anxiety 
treatment, unemployment benefits) to address alcohol use disorder during 
COVID-19
Disparities in alcohol 
consumption by sex and 
race/ethnicity
- Identify high-risk populations who may benefit from targeted interventions
- Assess effects of concurrent non-COVID-19-related stressors including 
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Alcohol Use Disorder Treatments during COVID-19 Pandemic
Efficacy of remote alcohol use 
counseling and monitoring
- Inform reimbursement policy in the post-COVID-19 era
- Assess benefits of continuing remote alcohol use treatment for select 
patients
- Determine care delivery models (e.g. telemedicine, video counseling) that 
are best suited for alcohol use disorder
Downstream Effects of COVID-19 on ALD
Incidence of alcohol-associated 
hepatitis, alcohol-associated-
acute-on-chronic liver failure 
and cirrhosis
- Address disparities by sex and race/ethnicity
- Better account for hepatology care needs in the post-COVID-19 era
- Expansion in alcohol use disorder counseling resources
Transplant considerations for 
ALD patients who relapsed
- Inform transplant listing policy decisions for patients who experience 
relapse during COVID-19 pandemic
A
cc
ep
te
d 
A
rt
ic
le
